Back

Prevalence and Clinical Significance of Adult-Onset Cancer Predisposition Variants in Pediatric Oncology

Maciaszek, J. L.; Pastor Loyola, V.; Cain, T.; Cardenas, M.; Blackburn, P. R.; Wilkinson, M. R.; Koo, S. C.; Wu, C.-H.; Li, C.; Wang, L.; Nichols, K. E.; Klco, J. M.; Eldomery, M. K.

2026-06-08 genetic and genomic medicine
10.64898/2026.06.07.26354365 medRxiv
Show abstract

Purpose: Pathogenic or likely pathogenic (P/LP) variants are increasingly identified in genes more commonly associated with adult-onset cancer predisposition, but their prevalence and relevance to children who present with cancer remain unclear. Methods: We retrospectively analyzed 1,280 consecutive pediatric patients with cancer who underwent clinical germline sequencing, using a virtual panel, from 2021 to 2024. Genes with P/LP variants were categorized as aoCPG or pediatric-onset cancer predisposition genes (poCPG) according to cancer risk before age 18 years and pediatric surveillance recommendations. Variant relevance was adjudicated using tumor diagnosis/histopathology, immunohistochemistry, and tumor molecular features and classified as primary, secondary, or indeterminate. Results: Among 1,280 patients, 197 (15.4%) harbored 211 P/LP variants across 54 genes. Sixty-six variants (31.3%) occurred in aoCPG, 87 (41.2%) in poCPG, and 58 (27.5%) were heterozygous variants in autosomal recessive genes. Among adult-onset variants, 7 (10.6%) were primary, 54 (81.8%) secondary, and 5 (7.6%) indeterminate. Among pediatric-onset variants, 77 (88.5%) were primary and 10 (11.5%) secondary. Six patients (3 adult-onset variants; 3 pediatric-onset variants) received targeted therapy informed by germline/somatic sequencing results. Conclusion: In pediatric oncology, most variants in aoCPG are secondary rather than tumor-related findings. Tumor-informed interpretation, beyond variant classification, may improve reporting, counseling, and therapeutic decision-making

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Genetics in Medicine
69 papers in training set
Top 0.1%
38.0%
2
Annals of Oncology
13 papers in training set
Top 0.1%
6.4%
3
Frontiers in Oncology
95 papers in training set
Top 0.7%
4.9%
4
npj Precision Oncology
48 papers in training set
Top 0.1%
4.4%
50% of probability mass above
5
Cancers
200 papers in training set
Top 1%
4.4%
6
Cancer Medicine
24 papers in training set
Top 0.2%
4.3%
7
Genome Medicine
154 papers in training set
Top 2%
4.0%
8
The Journal of Molecular Diagnostics
36 papers in training set
Top 0.1%
3.6%
9
Scientific Reports
3102 papers in training set
Top 46%
2.5%
10
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.2%
2.4%
11
PLOS ONE
4510 papers in training set
Top 46%
2.4%
12
Human Mutation
29 papers in training set
Top 0.3%
2.1%
13
European Journal of Cancer
10 papers in training set
Top 0.2%
1.5%
14
JAMA Network Open
127 papers in training set
Top 3%
1.2%
15
Cancer Research Communications
46 papers in training set
Top 1%
0.8%
16
Neuro-Oncology
30 papers in training set
Top 0.7%
0.8%
17
International Journal of Cancer
42 papers in training set
Top 1%
0.8%
18
JCO Precision Oncology
14 papers in training set
Top 0.4%
0.8%
19
European Journal of Human Genetics
49 papers in training set
Top 1%
0.8%
20
JNCI Cancer Spectrum
10 papers in training set
Top 0.5%
0.8%
21
Molecular Cancer Therapeutics
33 papers in training set
Top 0.7%
0.7%
22
Acta Neuropathologica
51 papers in training set
Top 1%
0.7%
23
Nature Communications
4913 papers in training set
Top 66%
0.6%
24
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.7%
0.6%
25
Open Forum Infectious Diseases
134 papers in training set
Top 3%
0.5%
26
Nature Medicine
117 papers in training set
Top 7%
0.5%
27
Clinical Chemistry
22 papers in training set
Top 1%
0.5%
28
Journal of Clinical Pathology
12 papers in training set
Top 0.7%
0.5%